@ShahidNShah


Why Some Cancer Drugs May Be Ineffective?
Posted via sciencedaily.comA possible explanation for why many cancer drugs that kill tumor cells in mouse models won't work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.
The research was published today in Nature Communications.
In the study, investigators reported the extensive presence of mouse viruses in patient-derived xenografts (PDX). PDX models are developed by implanting human tumor tissues in immune-deficient mice, and are commonly used to help test and develop cancer drugs.
"What we found is that when you put a human tumor in a mouse, that tumor is not the same as the tumor that was in the cancer patient," said W. Jim Zheng, PhD, professor at the School of Biomedical Informatics and senior author on the study. "The majority of tumors we tested were compromised by mouse viruses."
Using a data-driven approach, researchers analyzed 184 data sets generated from sequencing PDX samples. Of the 184 samples, 170 showed the presence of mouse viruses.
The infection is associated with significant changes in tumors, and Zheng says that could affect PDX as a drug testing model for humans.
"When scientists are looking for a way to kill a tumor using the PDX model, they assume the tumor in the mouse is the same as cancer patients, but they are not. It makes the results of a cancer drug look promising when you think the medication kills the tumor -- but in reality, it will not work in human trial, as the medication kills the virus-compromised tumor in mouse," Zheng said.
See Also
- Not All EHR Are Created Equal
- Our Mental Health Crisis and Tech’s Role In It
- How Patient-Generated Data Contributes To Clinician Burnout
- Telemedicine Didn't Work Well For This Provider – Here's Why
- A Roadmap for Value-Based Payment in 2030
Next Article
Not All EHR Are Created Equal
Having written about EMR and EHR software for 15 years, it’s amazing to think how far we’ve come. When I first started writing about EMR software, we were also talking about putting high speed …